December 7-8, 2006 - Denver, Colorado, USA
- 1-1/2 days, 14 speakers, 159 learners, no commercial exhibitors, no posters presented.
- Learner type: 82% Research Scientists, 14% Clinicians, and 4% Other.
- Credit type: ACCME, ANCC and ACPE.
- This symposium featured experts in the fields of cancer biology and pharmacology. The faculty addressed topics including animal models and imaging, TRAIL-mediated pathways and tyrosine kinase receptors.
- 100% of learners reported that the content was free from commercial bias.
- 93% of learners reported that the content was scientifically rigorous.
- 100% of learners reported that they would recommend this program to a colleague.
- Objectives of the course were to:
- Identify key components of signaling transduction pathways in cancer.
- Review current research on tyrosine kinase receptors.
- Learn how imaging techniques are utilized for cancer detection.
- Understand the use of animal models in developing cancer therapies.
- Describe the current cancer therapies.
- Selected learner comments included:
- “The level of speakers was great and talks were very informative and relevant to the topic.”
- “Broad range of information, generally interesting/applicable.”
- “Thanks, this was a fun program to attend. I learned a lot!”
- “Informative – it’s a toss up – could go for broader topics and not go as deep, the downside of the format of this symposia was it was rather narrow focus, the title didn’t necessarily indicate this.”
- “Good basic science, helps tie concepts together.”
- “Would highly recommend this program. Excellent symposium, would strongly encourage similar programs and hopefully future programs can be expanded to include Canada as this would generate high interest and exceptionally useful for fostering further research. High quality, interesting topics, excellent speakers.”
- Selected comments about the speakers included:
- “Great overview, provocative and stimulating.”
- “Somewhat more difficult to understand – a more basic level would have been helpful.”
- “Nice job explaining difficult concepts.”
- “Interesting way to look at ways to improve clinical drug development.”
- “Interesting topic outside what we commonly hear.”
- “Interesting way to screen for molecules.”
- “Good clinical perspective. Should have more translational talks from lab to clinic.”
- “Excellent talk and speaker – enjoyed analogies, made points clearer.”
- "Cool stuff!"
Disclosure of Faculty Relationships
BioSymposia, Inc. (formerly Serono Symposia International, Inc.) adheres to guidelines of the Accreditation Council for Continuing Medical Education (ACCME), the American Nurses Credentialing Center’s Commission on Accreditation (ANCCCA), the Accreditation Council for Pharmaceutical Education (ACPE), and all other professional organizations as applicable, stating that programs where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
As uses for pharmaceutical agents, medical devices, and other products may be presented in the program that are not necessarily the same as those indicated in approved product labeling (but which may reflect clinical experience, professional literature, other clinical sources known to the presenter, or investigational uses of products), we ask the presenter to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is simply intended to inform participants of any potential conflicts so that participants may form their own judgments based on full disclosure of the facts. Further, these opinions and recommendations presented during the program or materials related to the program do not imply an endorsement or recommendation on the part of BioSymposia, Inc. These presentations solely represent the independent views of the presenters/authors.
The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-FDA approved (off-label) uses of drugs:
Paul A. Bunn, M.D. discloses that his presentation will include discussion of off-label or otherwise non-approved uses of products with regard to Getfitnib and Cetuximab in lung cancer. The CME content over which Dr. Bunn has control contains information about healthcare products or services, and Dr. Bunn has had a financial relationship within the past 12 months in connection with these healthcare products or services (consultant for Imclone, Genentech, Elli Lilly, Sanofi-aventis).
Wafik El-Deiry, M.D. discloses that his presentation will include discussion of off-label or otherwise non-approved uses of products with regard to the potential of combining Sorafenib with TRAIL.
Douglas Yee, M.D. discloses that the CME content over which he has control contains information about healthcare products or services, and that Dr. Yee has had a financial relationship within the past 12 months in connection with these healthcare products or services, namely a research grant through Pfizer.
The following faculty indicated no significant relationship with commercial supporters and/or discussion of investigational or non-FDA approved (off-label) uses of drugs:
S. Gail Eckhardt, M.D.; Heide L. Ford, Ph.D.; Daniel L. Gustafson, Ph.D.; Manuel Hidalgo, Ph.D.; Tak W. Mak, Ph.D.; Raphael Nemenoff, Ph.D., David Piwnica-Worms, M.D., Ph.D.; Natalie Serkova, Ph.D.; Alexander Sorkin, M.D.; Tin Tin Su, Ph.D.; Andrew Thorburn, Ph.D.; and Marileila Varella Garcia, Ph.D.
Commercial Support and Other Disclosures
BioSymposia, Inc. (formerly Serono Symposia International, Inc.) is a 501(c)3 non-profit organization. All of our programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers and do not represent an endorsement or recommendation on the part of BioSymposia, Inc.
This program was supported by an unrestricted educational grant from EMD Serono, Inc. In addition, BioSymposia personnel are employees of EMD Serono, Inc. and BioSymposia, Inc. also receives other in-kind support from EMD Serono, Inc. in the form of space and administrative services.
Printer friendly version Signaling Transduction Modulators in Cancer Therapy
